Although technical advances enable normal epicardial coronary artery blood flow to be restored in most patients suffering myocardial infarction, restoration of blood flow is not always followed by improved myocardial perfusion. Recently, therefore, interest in the assessment of myocardial perfusion has grown, and a number of different assessment methods are available. The aim of this article was to provide an evaluation of the additional information that can be obtained from the widely used technique of conventional coronary angiography. We present a review of the data on epicardial coronary artery blood flow (both semiquantitative and quantitative) and on microvascular blood flow that can be obtained using coronary angiography and discuss their prognostic significance.

Key words: Coronary angiography. Coronary blood flow. Myocardial perfusion.

INTRODUCTION
The main aim in treating acute myocardial infarction (AMI) is to restore patency in the epicardial coronary artery. The theory of the “open artery” is based on two fundamental factors: time (as soon as possible) and size (as much flow as possible). Whatever the reperfusion method used, as demonstrated in many studies, \(^1\) the final aim is that the angiographic parameter, epicardial blood flow, is normal. Given that the latest developments make it possible to restore “normal” epicardial flow in more than 90% of the patients and that, given this is achieved, a significant number of patients still have unresolved ST segment and their myocardial perfusion is not restored under myocardial contrast echocardiography (MCE), interest has shifted from the epicardial arteries towards myocardial perfusion. There are several methods to assess the state of coronary microcirculation and myocardial perfusion, from the simplest—analyzing a previously resolved ST-segment elevation in the electrocardiogram (ECG), \(^1\) to the more complex—positron emission tomography (PET). \(^2\) The aim of this article is to review the findings obtained with coronary angiography \(^1\) to assess the quality of both epicardial and microvascular reperfusion.

RELEVANCE AND LIMITATIONS OF ASSESSING EPICARDIAL FLOW
Open Epicardial Artery: TIMI Flow Grading

The evaluation of blood flow in the epicardial coronary artery was formalized 20 years ago by the TIMI (Thrombolysis In Myocardial Infarction) Study Group, Harvard Medical School, Boston, Massachusetts, USA. Although technical advances enable normal epicardial coronary artery blood flow to be restored in most patients suffering myocardial infarction, restoration of blood flow is not always followed by improved myocardial perfusion. Recently, therefore, interest in the assessment of myocardial perfusion has grown, and a number of different assessment methods are available. The aim of this article was to provide an evaluation of the additional information that can be obtained from the widely used technique of conventional coronary angiography. We present a review of the data on epicardial coronary artery blood flow (both semiquantitative and quantitative) and on microvascular blood flow that can be obtained using coronary angiography and discuss their prognostic significance.

Key words: Coronary angiography. Coronary blood flow. Myocardial perfusion.
reinfarction, 30-32 mortality, 2-6, 33, 34 free wall rupture, 35 development of ventricular aneurysm 36 or the appearance of arrhythmias. 37-40 This correlation with prognosis, which was initially described for thrombolytic treatment in acute myocardial infarction (AMI), has also been extended to percutaneous coronary intervention therapy (PCI). 39-44 This relationship has been shown to be so strong that TIMI 3 flow is normally used as a parameter to evaluate the efficacy of different treatments instead of the relevant clinical events. 43-52 This classification allows us to establish the superiority of TIMI 3 flow over other parameters, even over TIMI grade 2: 2 meta-analyses 33, 34 report that early mortality was significantly lower among patients with TIMI 3 flow at 90 min after fibrinolysis than in the group with TIMI 2 flow (3.7% vs 6.6%; odds ratio [OR] =0.55; 95% confidence interval [CI], 0.4-0.76) or than in group with TIMI 0 or TIMI 1 flows (9.2%; OR=0.38; 95% CI, 0.29-0.5). With the development of repatency therapy using PCI, the use of these predictors has continued to prove their validity, 41 although some studies point out that the difference in mortality between TIMI 2 and 3 grades might not be so marked nowadays with the use of invasive therapies that combine fibrinolytic drugs and PCI. 23 On the other hand, technical developments in the intervention field (e.g. stenting, 53, 54 thrombectomy devices, 55, 56 distal protection systems 57-60) have not been associated universally with an improvement in TIMI flow. Nevertheless, this grading system has some limitations:

1. The most relevant limitation is its subjectivity, which leads to important discrepancies, 61 even when

### TABLE 1. Epicardial Flow and Myocardial Perfusion Grading Systems

<table>
<thead>
<tr>
<th>Grade</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Absence of antegrade flow after the occlusion point</td>
</tr>
<tr>
<td>1</td>
<td>The contrast agent passes through the occluded area, without opacifying the entire length of the artery by the end of the injection</td>
</tr>
<tr>
<td>2</td>
<td>The contrast agent opacifies the entire artery, but is remarkably slower in the non-culprit arteries or in the area proximal to the occluded section of the artery. A later subclassification distinguishes between grade 2a (slow filling, within 5 heart beats), grade 2b (slow filling in more than 5 heart beats) and grade 2c (normal filling, slow washout)</td>
</tr>
<tr>
<td>3</td>
<td>Normal antegrade flow and contrast clearance, similar to those in non-culprit arteries or proximal to the occluded section of the artery</td>
</tr>
<tr>
<td>4</td>
<td>Antegrade flow and clearance of contrast is faster than in non-culprit arteries</td>
</tr>
<tr>
<td></td>
<td><strong>Microvascular flow: TIMI myocardial perfusion grades (TMPG)</strong></td>
</tr>
<tr>
<td>0</td>
<td>Absence or minimum blush of the myocardium in the distribution section of the culprit artery</td>
</tr>
<tr>
<td>1</td>
<td>Persistent myocardial blush; the contrast agent enters the microvasculature, but it does not normally pass to the venous phase: “persistent stain” is detected at the beginning of the next injection (≥30 s)</td>
</tr>
<tr>
<td>2</td>
<td>Delayed blush and washout of the myocardium: the myocardial stain is evident (maximum level or minimum decline in intensity) by the end of the injection (3 heart beats for washout)</td>
</tr>
<tr>
<td>3</td>
<td>Normal blush: entry and exit of the contrast agent from the microvascuature at normal speed (total or high washout of the dye within 3 heart beats)</td>
</tr>
<tr>
<td></td>
<td><strong>Microvascular flow: myocardial blush grades (MBG)</strong></td>
</tr>
<tr>
<td>0</td>
<td>Absence of myocardial blush or “persistent stain,” indicative of the contrast exiting the extracellular space</td>
</tr>
<tr>
<td>1</td>
<td>Minimal myocardial blush</td>
</tr>
<tr>
<td>2</td>
<td>Moderate myocardial blush, of smaller intensity than in the reference area supplied by the non-culprit ipsilateral or contralateral artery</td>
</tr>
<tr>
<td>3</td>
<td>“Normal” myocardial blush, similar to the reference area</td>
</tr>
</tbody>
</table>
the analyzers assessment is performed by core laboratories with wide experience.\textsuperscript{2,4,5}

2. The filling time of the left anterior descending coronary artery (LAD) is higher than in other arteries, because this is normally the longest artery. Given that the filling of this artery can be simultaneously compared with the filling of the circumflex artery, the tendency to assign a TIMI grade 2 flow is much greater than with the right coronary artery (RCA).\textsuperscript{64}

3. The TIMI group itself has modified (without much acceptance) the grading system to distinguish up to 3 different subgroups in TIMI 2\textsuperscript{65}, (Table 1). These changes include factors such as washout speed that will be later discussed.

4. Finally, we cannot discard the presence of factors that could significantly modify grading, such as the pressure and phase within the cardiac cycle at which the contrast injection is administered, the heart rate and blood pressure of the patient, the use of vasodilators, etc. The impact of these factors is discussed in the next section.

Open Epicardial Artery: Quantification. Corrected TIMI Frame Count

In the light of the potential limitations of the TIMI flow grading system, new evaluation systems have been developed that more deeply characterize flow and improve the reproducibility of results: the corrected TIMI frame count (cTFC) system developed by Gibson et al\textsuperscript{64} is the most widely validated. Basically, it quantifies the TIMI flow grade by measuring the time it takes the contrast agent to fill the entire length of the epicardial artery. In order to standardize the criteria, several distal bifurcations were defined to serve as “final landmarks”: the “whale’s tail” at the apex of the LAD, the longest total distance along which dye travels in the circumflex system and yet passes through the culprit lesion, and the first branch of the posterolateral artery in the right coronary artery (Figure 1). The difference in the number of frames between the last one and the first (where the contrast agent fills at least 70% of the arterial ostium and starts to move in an anterograde direction) constitutes the TIMI frame count.

Some of the methodological aspects of this system are outlined as follows:

1. As described,\textsuperscript{64} the length of the LAD is 1.7 times greater than the circumflex and the right coronary arteries. Thus, a correction factor was introduced in the TFC system when analyzing the LAD: the corrected TIMI frame count (cTFC) is the result of the absolute difference divided by the correction factor, 1.7.

2. All the values initially published as “frame counts” referred to the video format standard in the United States, NTSC: 30 frames per second. In order
The original definition of this parameter includes measuring unit: time in seconds. Table 2 shows the most relevant values and their equivalence.

<table>
<thead>
<tr>
<th>Recording Speed</th>
<th>Normal Values (Healthy Volunteers)</th>
<th>TIMI 3 Flow (After Infarction)</th>
<th>TIMI 4 Flow (After Infarction)</th>
</tr>
</thead>
<tbody>
<tr>
<td>30 frames/s</td>
<td>≤ 21</td>
<td>≤ 40</td>
<td>≤ 14</td>
</tr>
<tr>
<td>25 frames/s</td>
<td>≤ 18</td>
<td>≤ 33</td>
<td>≤ 12</td>
</tr>
<tr>
<td>12.5 frames/s</td>
<td>≤ 9</td>
<td>≤ 17</td>
<td>≤ 6</td>
</tr>
<tr>
<td>Seconds</td>
<td>≤ 0.7</td>
<td>≤ 1.3</td>
<td>≤ 0.5</td>
</tr>
</tbody>
</table>

The correlation with independent methods of coronary functioning assessment (e.g. coronary flow reserve assessed by Doppler guidewire) has also been demonstrated. In complete contrast, some studies report no correlation between cTFC and coronary flow reserve parameters as measured by Doppler guidewire or even with early mortality. However, these studies assessed the flow in a limited number of patients after PCI and not at baseline. Thus, it is reasonable not to find a correlation between the baseline flow assessed by this method and the hyperemic flow analyzed via Doppler guidewire.

This method has obvious advantages over the qualitative assessment of epicardial flow:

1. Given the quantitative character of the parameter, high reproducibility has been demonstrated.

2. This is an easy method that does not require special equipment and can be performed immediately after capturing angiographic images.

3. The cut-off points shown in Table 2 allow us to classify unclear epicardial flows.

Nevertheless, the method presents certain limitations as it has been found that some factors can significantly change the values calculated:

1. Heart rate. An increase of 20 heart beats/min shortens the count by 5 frames.
2. Using nitrates increases the count by 6 frames.
3. Injection during the protodiastolic period reduces the count by 3-6 frames.
4. When the LAD is the culprit artery of the infarction: in such cases the count is higher than in the other arteries by 8 frames, even after correcting for length and adjusting for other variables.

It has not been demonstrated whether the calculation is affected by patient-dependent factors (e.g. age, sex, body size, blood pressure, or cardiovascular risk factors) or by procedure-dependent factors (injection pressure or type of contrast agent).

Taking this method as a basis, another assessment system has been developed, not only for the epicardial blood flow, but also for microcirculation flow—the assessment of the coronary blood flow reserve by analyzing the relationship of cTFC at baseline and cTFC after the administration of intracoronary or intravenous adenosine. This parameter has been correlated with Doppler guidewire analysis, although other studies have not confirmed this.

**ASSESSMENT OF MYOCARDIAL PERFUSION AND MICROCIRCULATION**

**Open Microvasculature: Assessment. Myocardial Blush**

Since the classic descriptions of reperfusion injury and no reflow events were presented, the attempts to assess the state of myocardial perfusion after an infarction have increased. The resolution of the ST-segment is the simplest and most reproducible analysis. Another method widely used is the MCE which, apart from being a non-invasive method, can be quantified. In both cases, the results have been correlated with the appearance of subsequent events.

With the increasing implementation of PCI as the treatment of choice for AMI, the availability of an early angiography is quite frequent and this has permitted the development of the myocardial blush...
The qualitative character of this parameter makes analysis of MCE, thus the 2 or the angiography are analyzed. Their relationship between mortality and the evolution time appear. Figure 2 shows some examples of myocardial perfusion is shown by grades 0 in both systems; and major reperfusion injury (hemorrhagic transformation or persistent extravasation) are included in TMPG 1 and MBG 0, respectively. Cases of MBG 1 and 2 cannot really be extrapolated to the TMPG system, and so a subclassification has been proposed for these cases: the TMPG 0.5. Thus, the 2 systems are not as different as they initially appear. Figure 2 shows some examples of myocardial perfusion analysis.

Although the existence of these 2 systems may bring into question the validity of the method, the fact is that TMPG2,24 and MBG25,26,27,30,31 correlate with mortality (Figure 3), even when only TIMI grade 3 flow patients are included. The influence of these parameters has also been shown in the percentage of myocardium salvaged in respect to the risk area30 and the mortality in patients in shock31 or on the relationship between mortality and the evolution time of AMI.34,35 On the other hand, a correlation has been found between these systems and other parameters independently related with prognosis after infarction, such as the analysis of coronary flow reserve with Doppler guidewire,107,108 and MCE,25,45,55 analysis of infarction size by single photon emission computed tomography (SPECT)56 or resolution of ST-segment elevation.109,110,111

The assessment of myocardial blush has its own limitations:

1. The qualitative character of this parameter makes it inherently subjective. Thus, intra- and inter-observer consistency is limited, as described by one of the groups with the greatest experience.25 In most studies, the analysis of MBG or TMPG is performed in central laboratories, and thus, the consistency with the assessments carried out by other observers might not be suitable.

2. Many of the studies carried out tend to group patients with MBG 2 and 3 or TMPG 2 and 3 into a single group with suitable perfusion. Given that it has been demonstrated that the prognosis of patients with TIMI 2 and TIMI 3 flow is not equivalent, this simplification of the system is most probably wrong.

3. Nevertheless, the fundamental limitation is not methodological, but refers to the unsolved challenge of treating suboptimal myocardial perfusion after coronary repatency. Table 3 sums up evidence published in this domain.

The correlation between the analysis of ST-segment resolution and myocardial blush is controversial because, although both have been related to clinical events, they do not always seem to match in every patient. What could be interpreted as a limitation tends to be assessed as another “anomalous” event, which are not uncommon in cardiology: the “electrical recovery” shown in the ECG is not always associated with integrity of the microvascular endothelium and recovery of perfusion, and vice versa. In fact, the 2 methods are complementary when the size of the infarction,14 or the angiography are analyzed. Their complementarity is also shown by the fact that the

<table>
<thead>
<tr>
<th>Drug/Method</th>
<th>Result</th>
<th>Study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Verapamil</td>
<td>Positive</td>
<td>Small studies25,26</td>
</tr>
<tr>
<td>Nicorandil</td>
<td>Positive</td>
<td>Small studies27,28</td>
</tr>
<tr>
<td>Cariprodine (Na+ pump inhibitor)</td>
<td>Positive (subgroup)</td>
<td>AMISSTAD II Study29</td>
</tr>
<tr>
<td>Abciximab (glycoprotein IIb/IIIa inhibitors)</td>
<td>Positive</td>
<td>Several studies101,102,103,104</td>
</tr>
<tr>
<td>Pexelizumab (complement inhibitor)</td>
<td>Pending</td>
<td>APEX AMI Study30</td>
</tr>
<tr>
<td>Hu23F2s (antibody anti-CD18)</td>
<td>Negative</td>
<td>HALT-MI Study31</td>
</tr>
<tr>
<td>Catirinet (Ca++-channel inhibitor)</td>
<td>Pending</td>
<td>EVOLVE Study32,33</td>
</tr>
<tr>
<td>Hypothermia</td>
<td>Non-conclusive</td>
<td>Preliminary studies13,14</td>
</tr>
<tr>
<td>Aqueous hyperoxygenation</td>
<td>Non-conclusive</td>
<td>Preliminary studies13,14</td>
</tr>
<tr>
<td>Thrombectomy devices</td>
<td>Positive</td>
<td>Small studies12,13,14</td>
</tr>
<tr>
<td>Distal protection devices</td>
<td>Negative</td>
<td>EMERALD Study30</td>
</tr>
</tbody>
</table>
group with a better prognosis after an infarction is the one where patients have both markers positive.133-135

There is ample literature available on the correlation between MCE and angiography.26,95-98,136 although a perfect correlation is not always found, even though both methods, at least theoretically, analyze myocardial perfusion. Bearing in mind that this is a dynamic event (some days after the infarction, many patients that initially did not show suitable myocardial blush may show a much better grade135), the discrepancies may be due to the behavior of the different contrast agent used—echographic contrast agents (microbubbles) always remain in the intravascular space, whereas radiological contrast media (and paramagnetic contrast used in magnetic resonance) often present extravascular passage, subsequently returning to the bloodstream. Thus, some authors137 argue that angiography or magnetic resonance do not actually assess myocardial perfusion, but rather capillary patency, the state of the endothelium, and the edema and interstitial hemorrhage i.e. reperfusion injury.

Figure 2. Examples of myocardial perfusion analysis. A: persistent stain of the septum (delimited by the arrows): grade 1 myocardial perfusion (TMPG), grade 0 myocardial blush (MBG) in LAD. B: persistent myocardial stain in the diaphragmatic territory: TMPG 1, MBG 5 grades in RCA. C: persistent capillary stain (small vessels are visualized) in RCA. D: lower intensity stain than in left coronary artery in the diaphragmatic territory (black arrow, TMPG 2 and MBG 2 grades) and barely present in posterolateral (white arrow, TMPG 0.5 and MBG 1 grades). E: normal myocardial stain (TMPG grade 3 and MBG grade 3) of left coronary artery; A donut-like image in LAO cranial projection. F: normal myocardial stain (TMPG 3 and MBG 3 grades) of RCA; example of digital subtraction (DSA).
Open Microvasculature: Quantification. Future Development

Myocardial perfusion assessed by angiography is analyzed by using several quantitative methods:

1. Methods based on digital subtraction angiography (DSA), widely used in vascular radiology, but little used in coronary angiography, may facilitate the quantification of the opacified area (in theory, this is “equivalent” to areas quantified in MCE), blush intensity (“MBG quantification”) or the speed at which the blush appears or disappears (“TMPG quantification”). For DSA to be more applicable, several studies are working on the development of techniques, such as moving mask, to attempt to neutralize the movements inherent to the heart.

2. A quantification system, based on cTFC has been suggested. This quantifies the number of frames between the entrance of the contrast agent into the myocardium and the peak blush intensity: the TIMI myocardial frame count. This count is significantly greater in patients with AMI with ST-segment elevation than in patients with NSTEACS.

3. Our group has developed a quantification system known as the Coronary Clearance Frame Count (CCFC) with good correlation with TMPG grades. Defined as “the inverse of cTFC,” it counts the difference in frames between the moment in which the...
contrast disappears from the arterial ostium and when it begins to disappear from the distal bifurcation described in the cTFC system. Although its potential clinical relevance has not been established yet, it shows correlation with myocardial perfusion TMPG grade 2 or 3, creating a cut-off point (45 images) that makes it possible to differentiate the better perfusion grades.

cTFC Analysis and Myocardial Blush. Practical Considerations

Both the quantitative analysis of epicardial blood flow (cTFC) and microvascular flow can be carried out online with current digital equipment, or offline with software for image review. Nevertheless, if the imaging conditions are not optimal, the interpretation and later analysis may be biased. Thus, some standard recommendations are made:

1. Imaging field: 23 cm. Not magnifying the image enables recording the whole length of the artery without the need for panning. This is particularly important for the correct analysis of myocardial blush, especially when DSA is used. The quality of current DSA images (fixed mask) is also highly dependent on maintaining apexes during the recording.

2. Imaging speed: ideally, 25 frames/s. Nevertheless, cTFC can be calculated at any recording speed, and subsequently it can be expressed in seconds or adjusted to the recommended speed.

3. Recording time: up to the appearance of contrast in the venous phase. This is very relevant for the TMPG analysis system. In this case, it is also particularly important to leave at least 30 s between one injection and the following one, and not to record immediately after contrast tests (it may incorrectly assign TMPG 1 values).

4. Selective projections:

   a) Analysis of cTFC. Recording images in PA or RAO projection (0°-30°) is recommended with caudal angulation (20°-30°) for the left coronary artery and in LAO projection (45°-60°) for the right coronary artery. 

   b) Blush analysis: the recommended projections differ from the previous ones, especially in the left coronary artery, where perfusion territories may be seen as overlapping. Thus, LAO projection (45°-60°) is recommended with cranial angulation (20°-30°), which makes it possible to see a donut-like image, or a left lateral projection (90°) in the case of the left coronary artery; for the right coronary artery, an LAO projection is recommended (45°-60°) with or without cranial angulation or RAO (30°).

   From a practical point of view, in our center we systematically analyze myocardial perfusion data from angiographies (according to both the TMPG and the MBG system) in all cases of angioplasty within the context of AMI and in other cases of intervention with no reflow events or slow final blood flow, reserving cTFC and CCFC for cases with difficult-to-classify epicardial blood flow or perfusion. In all these cases, the information obtained is always complemented by electrocardiographic analysis of ST-segment resolution.

CONCLUSIONS

Coronary angiography offers relevant but simple and easy to interpret information, not only on the state of the epicardial coronary circulation (TIMI flow in the epicardial artery and its quantification, TIMI frame count), but also on the state of microvascular circulation (myocardial blush grades: TIMI myocardial perfusion and myocardial blush grades). These data allow us to reliably assess the patient’s prognosis. The development of a quantitative variant of these techniques could improve their predictive power.

REFERENCES


mined non-invasive reperfusion indices in acute myocardial in-


29. Angrau B, Gandra H, Schmid A, Spronk D, et al. TIMI myocardial perfusion grade and ST segment re-

solution: association with infarct size as assessed by single phos-


31. Relik-van Wely L, Visser BF, van der Pol JM, Barabas PW, Barabas GI, et al. Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasmi-

nogen activator (Alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coro-


33. Fakhoury H, Farbood T, Al-Mohammad A, Brat KA. Significance of the Thrombolysis in Myocardial Infarction scor-


35. Cock CC, Kamp O, et al. Predictive value of markers of myo-


38. van’t Hof AW, Liem A, Suryapranata H, Hoornjec JC, de Boer MI, Zijlstra F. Angiographic assessment of myocardial reperfu-
sion in patients treated with primary angioplasty for acute myo-


39. Angeja BG, Gunda M, Murphy SA, Sobel BE, Rundle AC, Syed MJ, et al. TIMI myocardial perfusion grade and ST segment re-


41. Clemmensen F, Olman EM, Sevilla DC, Skottlen T, Wagner NB, Quispe PA, et al. Impact of infarct artery patency on the re-


42. Buszman P, Szafirzka A, Kalusz Z, Gassor M. Use of changes in ST segment elevation for prediction of infarct artery recanal-


mined non-invasive reperfusion indices in acute myocardial in-


46. Angrau B, Gandra H, Schmid A, Spronk D, et al. TIMI myocardial perfusion grade and ST segment re-

solution: association with infarct size as assessed by single phos-


68. Vrachalos AD, Alpert MA, Georgopoulos VP, Nikas DJ, Petropou- lou EN, Lazarets GI, et al. Comparative efficacy of primary an- gioplasty with stent implantation and thrombolysis in restoring

Pérez de Prado A et al. Coronary Angiography: Beyond Coronary Anatomy

Rev Esp Cardiol. 2006;59(6):596-608

605
basal coronary artery flow in acute ST segment elevation myo-
cardial infarction: quantitative assessment using the corrected
71. Bickel C, Rippecht HJ, Maimaitiming A, Welk I, Blankeberg
S, Krümmerer F, et al. The superiority of TIMI frame count
in detecting coronary flow changes after coronary stenting com-
pared to TIMI Flow Classification. J Cardiovasc Interv. 2002;14:
464-73.
72. Capuzzo C, Puscas F, de Luca G, Cioppa P, Mazzarotto P,
Lescoé D, et al. Direct coronary stenting: effect on coronary
blood flow, immediate and late clinical results. Catheter Cardio-
73. Gibson CM, Dotani MI, Murphy SA, Marble SJ, Du Toit
KW, Michaels AD, et al. Correlates of coronary blood flow be-
fore and after percutaneous coronary intervention and their rela-
tionship to angiographic and clinical outcomes in the RESTORE
trial. Randomized Efficacy Study of Tiilofiban for Outcomes and
74. Maginia A, Gattoo P, Chaukida C, Voudias V, Perdelis G,
Cokkanos DV. Estimation of coronary flow reserve using the
Thrombolysis In Myocardial Infarction (TIMI) frame count met-
75. Baccin C, Derkas AE, Garrit KN, Higano ST, Holmes DR Jr,
Lerman A. Relation of Thrombolysis in Myocardial Infarction
(TIMI) frame count to coronary flow parameters. Am J Cardio-
76. Unman B, Nisanci Y, Sezer M, Unman S, Yilmaz E, Oflaz H,
et al. The relationship between corrected TIMI frame count and
myocardial fractional flow reserve. J Cardiovasc Interv. 2002;14:
125-6.
77. Chung SK, Kopel J, Scott M, Shevchuk L, Goodholt D, Bon
R, et al. Coronary flow velocity reserve does not correlate with
TIMI frame count in patients undergoing non-emergency percu-
taneous coronary intervention. J Am Coll Cardiol. 2004;44:
376-82.
78. Ohno Y, Hasho Y, Takakashi T, Yamaguchi K, Ogura R, Ogata
T, et al. Relation between the TIMI frame count and the degree
of microvascular injury after primary angioplasty in patients with
79. Bhatt DL, Ellis SG, Ivance TB, Crowe T, Balazi E, Dehony D,
et al. Corrected TIMI frame count does not predict 30-day ad-
verse outcomes after reperfusion therapy for acute myocardial
80. Abaci A, Oghuzhan A, Eryol NK, Ergin A. Effect of potential
confounding factors on the thrombolysis in myocardial infarc-
tion (TIMI) frame count and its reproducibility. Circulation.
1999;100:2122-3.
81. Gibson CM, Murphy S, Menown IB, Sequeira RF, Greene R,
et al. The relationship between corrected TIMI frame count and
myocardial perfusion in patients with acute anterior wall myocardial
82. Faile BA, Guzzo JA, Tate DA, Nichols TC, Smith SC, Dehmer
GJ. Effect of age, hemodynamics, body size, and other clinical
variables on the corrected TIMI frame count in myocardial infarc-
tion frame count used as an assessment of coronary blood flow. Am
83. Dodge JT Jr, Rizzo M, Nykiel M, Altmann J, Brenk
84. Gibson CM, Kirtane AJ, Murphy S, Altmann J, Wilk I, Blank-
85. Gibson CM, Dotani MI, Murphy SA, Marble SJ, Du Toit
KW, Michaels AD, et al. Correlates of coronary blood flow be-
before and after percutaneous coronary intervention and their rela-
tionship to angiographic and clinical outcomes in the RESTORE
trial. Randomized Efficacy Study of Tiilofiban for Outcomes and
al. Temporal changes in myocardial perfusion patterns in pa-
ents with reperfused anterior wall myocardial infarction: their
87. Ito H, Masumya A, Ikawa K, Takachi S, Masumya T, Hori
M, et al. Clinical implications of the ‘no reflow’ phenomenon. A
 predictor of poor recovery of left ventricular function in anterior
88. Ito H, Okamura A, Ikawa K, Masumya T, Hori M, Takachi
S, et al. Myocardial perfusion patterns related to thrombolysis in
myocardial infarction perfusion grades after coronary angio-
plasty in patients with acute anterior wall myocardial infarction.
89. Asanuma T, Tanabe K, Ochiai K, Yoshitomi H, Nakamura K,
Murakama Y, et al. Relationship between progressive microvas-
cular damage and intramyocardial hemorrhage in patients with
90. Ito H, Ikawa K. Assessing the relation between coronary re-
91. Rupajtis M, Camarazo G, Kaul S, Pories ER, Sarembok J,
Giurleo LW. Microvascular integrity indicates myocardial vi-
92. Greaves K, Dixon SB, Fejka M, O’Neill WR, Redwood SR,
Murber RS, et al. Myocardial contrast echocardiography is su-
perior to other known modalities for assessing myocardial re-
perfusion after acute reperfusion therapy for acute myocardial
infarction. Heart. 2003;89:139-44.
93. Boal V, Sanchez J, Lopez-Lopez MG, Llober A, Pellizer M,
Lo-
sada A, et al. Estudio de perfusión en pacientes postinfarto me-
diante ecografía miocárdica con inyección de contraste intraco-
ráurico. Implicaciones y relación con la angiografía y la
94. Bolognesi L, Ducci K, Angioli P, Falsini G, Liistro F, Baldasa-
nere S, et al. Elevations in troponin I after percutaneous coronary
interventions are associated with abnormal tissue-level perfu-
sion in high-risk patients with non-ST-segment-elevation acute
95. Murakami Y, Ikawa K, Kajita T, Krook K, Morokawa M, Po-
dolec P, Zalewski J, et al. The value of myocardial contrast echocar-
diography compared with SPECT in detecting myocardial perfu-
sion abnormalities in patients with anterior acute myocardial in-
96. Gibson CM, Schomig A. Coronary and myocardial angi-
ography: angiographic assessment of both epicardial and myo-
D, B暄k H, Dosselaar J, et al. Angiographic assessment of reper-
fusion in acute myocardial infarction by myocardial blush grade. Cir-
98. Haeger PK, Christoff P, Heussen N, Leppe W, Hannaf P, Hoff-
mann K. Prediction of clinical outcome after mechanical re-
vascularization in acute myocardial infarction by markers of myo-
110. Werner GS, Lang K, Kuehnert H, Figulla HR. Intracoronary vesi-
cular and myocardial salvage in patients with acute myocardial
al. Assessment of myocardial reperfusion in patients with
ST-segment elevation myocardial infarction treated with primary
113. Hoffmann R, Haager P, Lepper W, Franke A, Hanrath P. Rela-
tion of coronary flow pattern to myocardial blush grade in pa-
tients with first acute myocardial infarction. Heart. 2003;89:
114. Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW.
A randomized, double-blinded, placebo-controlled multicenter
study of intracoronary aqueous oxygen therapy. J Am Coll Cardiol.
2002;40:1199-204.
115. Sato H, Kitada Y. Cardioprotective effect of MCC-135 is asso-
ciated with inhibition of Ca2+ overload in ischemic/reperfused
MR, et al. A randomized, double-blind, placebo-controlled study of the safety and efficacy of intracoronary MCC-135 as an adju-
vant to primary percutaneous coronary intervention in pa-
tients with acute myocardial infarction: rationale and design of the evalua-
tion of MCC-135 for left ventricular salvage in acute MI (EVOLVE)
117. Dixon BP, Gibbons RJ, Chomos NA, Garbel PA, Sheehan F. The
effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with
direct angioplasty: the results of the HALT-MI study. J Am Coll Cardiol.
2002;40:1199-204.
118. Sabih N, Kitada Y. Cardioprotective effect of MCC-135 is asso-
ciated with inhibition of Ca2+ overload in ischemic/reperfused
119. Razzolini R, et al. Pressure response to vasopressors and morta-
lity after direct angioplasty for cardiogenic shock. Int J Cardiat.
120. de Luca G, van’t Hof AW, de Boer MF, Ottevanger JP, Hoornije
JC, Gouwink AK, et al. Time-to-treatment significantly affects the extent of ST-segment resolution and myocar-
122. Gibson CM, Murphy SA, Kirtane AJ, Giugliano RP, Cannon
JC, Gosselink AT, et al. Symptom-onset-to-balloon time and mortal-
ity after direct angioplasty for cardiogenic shock. Int J Cardiat.
123. Pérez de Prado A, Fernández-Vázquez F, Cuellas JC, Alomos
Oracouz N, Carbonell R, Pascual C, et al. Association between lo-
cal platelet inhibition after cardiac arrest and myocardial reper-
124. Armstrong PW, Adams PX, Al-Khalidi HR, Hoom C, Holmes
D, O’Neill W, et al. Assessment of PeriInfarctaum in Acute Myocar-
dial Infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of peri-
125. Dixon BJ, Whithurst RJ, Dawe WM, Grebe J, Sherman W, Shacer
GL, et al. Induction of mild systemic hypothermia with endo-
vascular cooling during primary percutaneous coronary in-
tervention for acute myocardial infarction. J Am Coll Cardiol.
2002;40:1928-34.
126. Ly BQ, Denault A, Dupuis J, Vadeboncoeur A, Hard F, Arse-
gear with cariporide to prevent myocardial infarction in high-risk ischemic syndromes. Main results of the GUARDIAN trial. Guard during ischemia against necrosis (GUARDIAN) Investi-
2005;45:1758-63.
128. Badelló D, Bortol S, Zunzunèa K, Kita M, Legatko J, Wiernik-
ski M, et al. Assessment of myocardial reperfusion in patients with acute myocardial infarction treated with combination of fibrin-
129. Kaul U, Gupta RK, Haridas KK, Ramesh SS, Sells KK, Singh
Preservation of myocardial microcirculation during mechanical
131. Bellandi F, Marosi M, Gallipoli M, Tuso A, Dabizzi RP. Increa-
sse of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary oc-
132. Constantini CO, Stone GW, Mehlan A, Aymong E, Grines CL,
Cox DA, et al. Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocar-
133. Pérez de Prado A, Fernández-Vázquez F, Cuellas JC, Alomos
Oracouz N, Carbonell R, Pascual C, et al. Association between lo-
cal platelet inhibition after cardiac arrest and myocardial reper-
134. Armstrong PW, Adams PX, Al-Khalidi HR, Hoom C, Holmes
D, O’Neill W, et al. Assessment of PeriInfarctaum in Acute Myocar-
dial Infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of peri-
135. Dixon BJ, Whithurst RJ, Dawe WM, Grebe J, Sherman W, Shacer
GL, et al. Induction of mild systemic hypothermia with endo-
vascular cooling during primary percutaneous coronary in-
tervention for acute myocardial infarction. J Am Coll Cardiol.
2002;40:1928-34.
136. Ly BQ, Denault A, Dupuis J, Vadeboncoeur A, Hard F, Arse-
gear with cariporide to prevent myocardial infarction in high-risk ischemic syndromes. Main results of the GUARDIAN trial. Guard during ischemia against necrosis (GUARDIAN) Investi-
2005;45:1758-63.
138. Badelló D, Bortol S, Zunzunèa K, Kita M, Legatko J, Wiernik-
ski M, et al. Assessment of myocardial reperfusion in patients with acute myocardial infarction treated with combination of fibrin-
139. Kaul U, Gupta RK, Haridas KK, Ramesh SS, Sells KK, Singh
Preservation of myocardial microcirculation during mechanical


